ABSENCE OF PHARMACOKINETIC INTERACTION OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B‐CELL NON‐HODGKIN'S LYMPHOMA (INHL)
Andres Forero‐Torres(Kirklin Clinic), Sumit Madan(Cancer Research Center), Petra Hoever(Actelion (Switzerland)), Jason C. Chandler(West Cancer Center), Abraham S. Kanate(HonorHealth), Miguel Izquierdo(University of Amsterdam), Vincent Duval(Novartis (Switzerland)), Michelle Quinlan(Nottingham University Hospitals NHS Trust), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
The drug resistance-related protein LRP is the human major vault protein
|Nature Medicine|1995|619
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
|Clinical Cancer Research|2015|355